Eptifibatide Brand Name– Integrilin
What is Eptifibatide
Eptifibatide is a cyclic peptide platelet glycoprotein IIb/IIIa inhibitor.
Eptifibatide contains 6 amino acids and one mercaptopropionyl residue. Cyclic peptides are more resistant to degradation than linear peptides, but still have short half-lives because they are broken down in the body.
Eptifibatide has a shorter half-life than abciximab and its effects on circulating platelets wear off more quickly.
Preclinical and clinical studies indicate that eptifibatide is not immunogenic, most likely because of its low molecular weight.
Eptifibatide (in combination with aspirin and heparin) is indicated for use in patients undergoing PCI as well as for the treatment of unstable angina or acute ST-elevation myocardial infarction.
Eptifibatide was FDA-approved in May 1998.
The FDA approved a revised eptifibatide dosing regimen for coronary stent intervention on June 12, 2001, based on the ESPRIT study findings of reduced morbidity (composite endpoint of reduced death, MI, or urgent revascularization)
Indications
- acute myocardial infarction, NSTEMI
- acute myocardial infarction, STEMI
- myocardial infarction prophylaxis
- percutaneous coronary intervention (PCI)
- unstable angina
For the adjunctive treatment of patients undergoing percutaneous coronary intervention (PCI), including those undergoing coronary stenting, to prevent cardiac ischemic complications (e.g., myocardial infarction prophylaxis)
Side Effects
- anaphylactic shock
- anaphylactoid reactions
- antibody formation
- bleeding
- GI bleeding
- hematemesis
- hematuria
- hypotension
- intracranial bleeding
- platelet dysfunction
- retroperitoneal bleeding
- stroke
- thrombocytopenia
Monitoring Parameters
- activated partial thromboplastin time (APTT)
- clotting time
- hemoglobin/hematocrit
- platelet count
- serum creatinine/BUN
- thrombin time
Contraindications
- anticoagulant therapy
- bleeding
- breast-feeding
- coagulopathy
- dialysis
- geriatric
- hypertension
- intramuscular injections
- pregnancy
- renal disease
- renal failure
- renal impairment
- stroke
- surgery
- thrombocytopenia
- thrombolytic therapy
- trauma
- venipuncture
Interactions
- Acetaminophen; Aspirin, ASA; Caffeine
- Ado-Trastuzumab emtansine
- ADP receptor antagonists
- Altretamine
- Aminolevulinic Acid
- Anagrelide
- Antimetabolites
- Antithrombin III
- Antithymocyte Globulin
- Apixaban
- Argatroban
- Arsenic Trioxide
- Aspirin, ASA
- Aspirin, ASA; Butalbital; Caffeine
- Aspirin, ASA; Butalbital; Caffeine; Codeine
- Aspirin, ASA; Caffeine; Dihydrocodeine
- Aspirin, ASA; Caffeine; Orphenadrine
- Aspirin, ASA; Carisoprodol
- Aspirin, ASA; Carisoprodol; Codeine
- Aspirin, ASA; Citric Acid; Sodium Bicarbonate
- Aspirin, ASA; Dipyridamole
- Aspirin, ASA; Omeprazole
- Aspirin, ASA; Oxycodone
- Aspirin, ASA; Pravastatin
- Betrixaban
- Bexarotene
- Bivalirudin
- Chlorambucil
- Cilostazol
- Cladribine
- Clofarabine
- Collagenase
- Dabigatran
- Dalteparin
- Danaparoid
- Danazol
- Dasatinib
- Defibrotide
- Denileukin Diftitox
- Desirudin
- Desvenlafaxine
- Dipyridamole
- Drotrecogin Alfa
- Duloxetine
- Edoxaban
- Enoxaparin
- Estramustine
- Fish Oil, Omega-3 Fatty Acids (Dietary Supplements)
- Fludarabine
- Folate analogs
- Fondaparinux
- Garlic, Allium sativum
- Ginger, Zingiber officinale
- Ginkgo, Ginkgo biloba
- Green Tea
- Heparin
- Ibritumomab Tiuxetan
- Ibrutinib
- Icosapent ethyl
- Iloprost
- Imatinib
- Inotersen
- Intravenous Lipid Emulsions
- Lepirudin
- Levomilnacipran
- Lomustine, CCNU
- Mercaptopurine, 6-MP
- Methoxsalen
- Methylsulfonylmethane, MSM
- Milnacipran
- Mycophenolate
- Nelarabine
- Nonsteroidal antiinflammatory drugs
- Obinutuzumab
- Pegaspargase
- Pentosan
- Pentostatin
- Pentoxifylline
- Phentermine; Topiramate
- Photosensitizing agents (topical)
- Prasterone, Dehydroepiandrosterone, DHEA (Dietary Supplements)
- Prasterone, Dehydroepiandrosterone, DHEA (FDA-approved)
- Purine analogs
- Rivaroxaban
- Selective serotonin reuptake inhibitors
- Selumetinib
- Sodium Hyaluronate, Hyaluronic Acid
- Sulfinpyrazone
- Thioguanine, 6-TG
- Thrombolytic Agents
- Tinzaparin
- Tipranavir
- Topiramate
- Trazodone
- Treprostinil
- Tretinoin, ATRA
- Venlafaxine
- Verteporfin
- Vilazodone
- Vorapaxar
- Vorinostat
- Vortioxetine
- Warfarin
